All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
The development of multiple myeloma (MM) can be preceded by premalignant conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Due to the risk of progression, both conditions are usually monitored with regular follow-up visits, which can have a detrimental psychosocial impact on a patient’s quality of life. Previous studies investigating health-related quality of life (HRQoL), psychological distress (DT) and mental comorbidity in patients with MM have shown impairment in HRQoL and increased DT associated with disease- and treatment-related events.1,2 This study was carried out in Germany by Imad Maatouk, Medical University Hospital and National Center for Tumor Diseases, Heidelberg, and colleagues, and compared HRQoL, DT, anxiety and depression rates between patients with MGUS/SMM and patients with MM pre- and post-treatment.3
All data are given as Group 1 (premalignant disease) vs Group 2 (new diagnosis) vs Group 3 (treated)
Lower physical HRQoL scores and higher depression scores were observed in patients with MM compared with patients with precursor disease. This is likely due to the symptoms of active MM and treatment-related adverse events.
There was no significant difference between mental HRQoL, distress and severity in anxiety symptoms between the three groups. This aligns with previous reports from clinicians that screening and anticipation of cancer in patients with MGUS and SMM can cause a similar psychosocial burden to those patients with active MM.1,2 The high DT score across all groups (~63%) highlights the need for psychosocial support in the majority of patients, including those with MGUS or SMM.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox